Table of Contents
Executive Summary
- 2007-2012 Market Dynamics
- Competitive Landscape
- Brand Overview
- Physician and Patient Perspectives: Findings of Our Primary Research
Chapter 1. Introduction
- Scope of the Report
- Survey Methodology
- Physician Demographics
- Patient Demographics
Chapter 2. Competitive Analysis
- Overview of Competitive Landscape
- Physician Perception of Key Brands
- Current Therapies
- Emerging Therapies
- Comparative Labeling for Key Brands
- Comparative Pricing of Key Brands
- Reimbursement Issues
- United States
- Europe
- Japan
- Promotional Spending
- Company-Specific Trends
- Brand-Specific Trends
- Physician and Caregiver Perceptions of Alzheimer's Brand Promotion
Chapter 3. Primary Research with Key Stakeholders
- Key Findings of Primary Research
- Physicians
- Key Drivers of Prescriber Decisions
- Sources of Information
- Response to Messaging
- Perceptions of Competitors
- Perceptions of Brands
- Unmet Needs in Alzheimer's Disease
- Caregivers
- Response to Messaging
- Perceptions of Brands
- Unmet Needs in Alzheimer's Disease
Chapter 4. Established Competitors
- Pfizer
- Strategic Overview
- Goals and Vision in Alzheimer's Disease
- Alzheimer's Disease Product Portfolio
- Current Positioning
- Physicians Inform Our Analysis
- Market Strategy and Outlook
- Eisai
- Strategic Overview
- Goals and Vision in Alzheimer's Disease
- Alzheimer's Disease Product Portfolio
- Current Positioning
- Physicians Inform Our Analysis
- Market Strategy and Outlook
- Aricept
- Current Positioning
- Physicians Inform Our Analysis
- Aricept Competitive Analysis
- Key Brand Strategies in the Alzheimer's Disease Market
- Lifecycle Management and Future Strategy
- Future Positioning and Outlook
- Novartis
- Strategic Overview
- Goals and Vision in Neuroscience
- Alzheimer's Disease Product Portfolio
- Current Positioning
- Physicians Inform Our Analysis
- Market Strategy and Outlook
- Exelon
- Current Positioning
- Physicians Inform Our Analysis
- Exelon Competitive Analysis
- Key Brand Strategies
- Lifecycle Management and Future Strategy
- Future Positioning and Outlook
- Johnson & Johnson
- Strategic Overview
- J&J Companies Currently Marketing Alzheimer's Disease Products
- Goals and Vision in Alzheimer's Disease
- Alzheimer's Disease Product Portfolio
- Current Positioning
- Physicians Inform Our Analysis
- Market Strategy and Outlook
- Razadyne
- Current Positioning
- Physicians Inform Our Analysis
- Razadyne Competitive Analysis
- Key Brand Strategies
- Lifecycle Management and Future Strategy
- Future Positioning and Outlook
- Forest Laboratories
- Strategic Overview
- Goals and Vision in Alzheimer's disease
- Alzheimer's Disease Product Portfolio
- Current Positioning
- Physicians Inform Our Analysis
- Market Strategy and Outlook
- Lundbeck
- Strategic Overview
- Goals and Vision in Alzheimer's disease
- Alzheimer's Disease Product Portfolio
- Current Positioning
- Market Strategy and Outlook
- Namenda
- Current Positioning
- Physicians Inform Our Analysis
- Namenda Competitive Analysis
- Key Brand Strategies
- Lifecycle Management and Future Strategy
- Future Positioning and Outlook
Chapter 6. Emerging Competitors
- Wyeth
- Strategic Overview
- Goals and Vision in Alzheimer's Disease
- Alzheimer's Disease Product Portfolio
- Elan
- Strategic Overview
- Goals and Vision in CNS
- Alzheimer's Disease Product Portfolio
- Bapineuzumab
- Development and Commercial Overview
- Bapineuzumab Competitive Analysis
- Future Positioning and Outlook
- Eli Lilly
- Strategic Overview
- Goals and Vision in Neuroscience
- Alzheimer's Disease Product Portfolio
- LY-2062430
- Development and Commercial Overview
- LY-2062430 Competitive Analysis
- Future Positioning and Outlook
- LY-450139
- Development and Commercial Overview
- Medivation
- Strategic Overview
- Goals and Vision in Alzheimer's Disease
- Alzheimer's Disease Product Portfolio
- Dimebon
- Development and Commercial Overview
- Dimebon Competitive Analysis
- Future Positioning and Outlook
Chapter 7. Market Forecast
- Alzheimer's Disease Market Analysis
- Sales by Region
- Key Trends in the U.S. Alzheimer's Disease Market, 2007-2012
- Key Trends in the European Alzheimer's Disease Markets, 2007-2012
- Key Trends in the Japanese Alzheimer's Disease Market, 2007-2012
- Market Share by Class
- Sales by Brand: Currently Available Therapies
- Key Trends in Aricept Alzheimer's Disease Sales, 2007-2012
- Key Trends in Exelon Alzheimer's Disease Sales, 2007-2012
- Key Trends in Razadyne Alzheimer's Disease Sales, 2007-2012
- Key Trends in Namenda Alzheimer's Disease Sales, 2007-2012
- Sales by Brand: Emerging Therapies
- Key Trends in Bapineuzumab and LY-2062430 Alzheimer's Disease Sales,
2007-2012
- Key Trends in Dimebon Alzheimer's Disease Sales, 2007-2012
- Sales by Company
- Appendices
- Epidemiology
- Prevalence and Diagnosis
- Major Markets Statistics and Key Findings
- Abbreviations Used in this Report
- Methodology
- Epidemiology
- Market Forecast
- Emerging Therapy Prices
- Companies Included in Competitive Analysis
Table of Exhibits
- Executive Summary
- Exhibit 1: Key Parameters of the Alzheimer's Disease Market
- Exhibit 2: Alzheimer's Disease Market ($US), Major Markets, 2007-2012
- Exhibit 3: Alzheimer's Disease Market Competitive Position, 2007 and 2012
- Exhibit 4: Alzheimer's Disease Market, by Company, as a % of Total, 2007
and 2012
- Exhibit 5: Alzheimer's Disease Sales ($US), as a Percentage of Total, 2007
and 2012
- Exhibit 6: Physician Top-of-Mind Companies in Alzheimer's Disease Treatment
- Exhibit 7: Physician Rankings of Current Alzheimer's Disease Treatments
- Exhibit 8: Caregiver Rankings of Top-of-Mind Alzheimer's Disease Treatments
- Exhibit 9: Surveyed Physicians' Years of Practice
- Exhibit 10: Surveyed Physicians' Patients per Month
- Exhibit 11: Surveyed Physicians' Geographic Distribution
- Exhibit 12: Surveyed Caregivers' Age
- Exhibit 13: Surveyed Caregivers' Gender
- Exhibit 14: Patient Age, Reported by Surveyed Caregiver
- Exhibit 15: Number of Years Caregiver has Taken Care of Alzheimer's
Disease Patient
- Exhibit 16: Number of Years Patient has Received Treatment for Alzheimer's
Disease,
- Reported by Surveyed Caregiver
- Exhibit 17: Patients' Healthcare Provider, Reported by Surveyed Caregiver
- Exhibit 18: Surveyed Patients' Severity of Alzheimer's Disease, Reported
by Caregiver
- Exhibit 19: Surveyed Caregivers' Relationship to Alzheimer's Disease
Patient
- Exhibit 20: Alzheimer's Disease Sales ($MM), by Country, 2007
- Exhibit 21: Alzheimer's Market Competitive Position, by Major Brands, 2007
and 2012
- Exhibit 22: Alzheimer's Disease Major-Market Sales ($MM), 2007-2012
- Exhibit 23: Physician Perception of Key Brands in Alzheimer's Disease
- Exhibit 24: Labeled Indications for Key Brands, 2008
- Exhibit 25: Current Price per Day ($), Key Brands, 2007
- Exhibit 26: Medicare Formulary Status of Leading Alzheimer's Disease Drugs
- Exhibit 27: U.S. Non-Medicare Formulary Status of Leading Alzheimer's
Disease Drugs
- Exhibit 28: Alzheimer's Disease Patients'- Primary Prescription Drug
Coverage, Reported by Surveyed Caregivers
- Exhibit 29: Caregiver Perception of Alzheimer's Disease Drug Pricing
- Exhibit 30: Reimbursement of Leading Alzheimer's Disease Drugs in Europe
and Japan
- Exhibit 31: Promotional Spend for Alzheimer's Disease Therapies, by
Company, 2007
- Exhibit 32: Promotional Spend for Alzheimer's Disease Therapies, by Brand,
2007
- Exhibit 33: Promotional Spending, by Competitor, as a % of Total Spending
for Agents in Alzheimer's Disease, 2006-2007
- Exhibit 34: Physician Perception of the Alzheimer's Drug with the Most
Promotional Material
- Exhibit 35: Advertising Seen by Caregivers, By Brand
- Exhibit 36: Alzheimer's Disease Treatment Patterns, by Major Market
- Exhibit 37: Preferred Information Sources for Physicians Who Treat
Alzheimer's Disease
- Exhibit 38: Sources of Information for Alzheimer's Disease for Caregivers
and Patients, Physician-Ranked
- Exhibit 39: Physician Response to Marketing Messages for a Hypothetical
Alzheimer's Brand
- Exhibit 40: Physician Perception of Most Influential Branded-Drug
Marketing Messages in the Alzheimer's Disease Market
- Exhibit 41: Physicians' Top-of-Mind Companies in Alzheimer's Disease
- Exhibit 42: Physician Rankings of the Current Reputation of Competitors in
the Alzheimer's Disease Market
- Exhibit 43: Physician Rankings of Alzheimer's Competitors, Based on
Currently Marketed Drugs' Attributes
- Exhibit 44: Physician Rankings of Alzheimer's Competitors, Summary
- Exhibit 45: Company Reputations in Alzheimer's Disease Treatment
- Exhibit 46: Physician Rankings of Alzheimer's Brands, Summary
- Exhibit 47: Physician Rankings of Currently Marketed Brands for
Alzheimer's Disease
- Exhibit 48: Physician Rankings of Alzheimer's Brands by Number of Patient
Requests
- Exhibit 49: Physician Perceptions of Unmet Needs in Alzheimer's Disease
- Exhibit 50: Physician Perceptions of Unmet Needs in Alzheimer's Disease
- Exhibit 51: Surveyed Caregivers' Relationship to Alzheimer's Disease
Patients
- Exhibit 52: Surveyed Patients' Severity of Alzheimer's Disease, Reported
by Caregiver
- Exhibit 53: Caregivers' Most-Trusted Sources for Alzheimer's Information
- Exhibit 54: Sources for Alzheimer's Information Used By Caregivers in the
Past Three Months
- Exhibit 55: Sources of Information for Requested Therapies
- Exhibit 56: Caregiver Response to Marketing Messages in Alzheimer's
Disease, Using Hypothetical “Brand X”
- Exhibit 57: Caregiver Perception of Influential Messaging in the
Alzheimer's Disease Market
- Exhibit 58: Caregiver Identification of Brand Messaging in the Alzheimer's
Disease Market
- Exhibit 59: Caregivers Top-of-Mind Alzheimer's Disease Therapies, by Brand
- Exhibit 60: Therapies Specifically Requested by Caregiver for an
Alzheimer's Disease Patient
- Exhibit 61: Alzheimer's Disease Patients'- Therapeutic History, by Brand
- Exhibit 62: Key Drivers of Alzheimer's Therapy Use, by Brand
- Exhibit 63: Reasons for Discontinuation of Alzheimer's Disease Therapies,
by Brand
- Exhibit 64: Caregiver Perception of Unmet Needs in Alzheimer's Disease
- Exhibit 65: Summary of Pfizer's Alzheimer's Disease Product Portfolio
- Exhibit 66: Physician Perceptions of Pfizer in Alzheimer's Disease
- Exhibit 67: Top-of-Mind Companies in Alzheimer's Disease
- Exhibit 68: Summary of Eisai's Alzheimer's Disease Product Portfolio
- Exhibit 69: Physician Perceptions of Eisai in Alzheimer's Disease
- Exhibit 70: Physician Perceptions of Aricept
- Exhibit 71: Currently Marketed AChEI Launch Dates, by Region
- Exhibit 72: The Effect of Aricept's Recent Expansion of Approved
Indications on Physicians' - Prescribing for Moderate to Severe AD Patients
- Exhibit 73: Percentage of Physicians Prescribing AD Drug Regimens
Off-Label to Treat MCI and Vascular Dementia
- Exhibit 74: Reasons Physicians Do Not Prescribe AD Drug Regimens Off-Label
to Treat MCI and Vascular Dementia
- Exhibit 75: Ongoing Eisai/Pfizer-Sponsored Clinical Trials for Aricept
- Exhibit 76: Aricept Alzheimer's Disease Sales ($US), by Region, 2007-2012
- Exhibit 77: Aricept Alzheimer's Disease Sales ($US), by Formulation,
2007-2012
- Exhibit 78: Aricept Alzheimer's Disease Sales, by Country, 2007-2012
- Exhibit 79: Summary of Novartis's Alzheimer's Disease Product Portfolio
- Exhibit 80: Physician Perceptions of Novartis in Alzheimer's Disease
- Exhibit 81: Physician Perceptions of Exelon
- Exhibit 82: Surveyed Physicians Who Prescribe Multiple AChEIs Favor
Specific Brands Second Line
- Exhibit 83: Physicians'- Method of Awareness of FDA Approval of the Exelon
Transdermal Patch
- Exhibit 84: The Effect of Exelon Transdermal Patch Availability in
Physician Prescribing for Mild to Moderate AD Patients
- Exhibit 85: Reasons Why the Exelon Patch May Not Change Prescribing
Behavior
- Exhibit 86: Physicians'- Expected Switching of Patients to Exelon Patch
from Aricept
- Exhibit 87: Physicians'- Reasons for Not Switching Patients to Exelon
Patch from Aricept
- Exhibit 88: Ongoing Novartis-Sponsored Phase III and IV Clinical Trials
for Exelon
- Exhibit 89: Exelon Alzheimer's Disease Sales ($US), By Region, 2007-2012
- Exhibit 90: Exelon Alzheimer's Disease Sales ($US), By Formulation,
2007-2012
- Exhibit 91: Exelon Alzheimer's Disease Sales, ($US) by Country, 2007-2012
- Exhibit 92: Summary of Johnson & Johnson's Alzheimer's Disease Product
Portfolio
- Exhibit 93: Physician Perceptions of Ortho-McNeil Neurologics in
Alzheimer's Disease
- Exhibit 94: Physician Perceptions of Janssen in Alzheimer's Disease
- Exhibit 95: Physician Perceptions of Razadyne
- Exhibit 96: Ongoing Industry-Sponsored Phase III and IV Clinical Trials
for Razadyne/Razadyne ER
- Exhibit 97: Razadyne Alzheimer's Disease Sales ($US), By Region, 2007-2012
- Exhibit 98: Razadyne Alzheimer's Disease Sales ($US), By Formulation,
2007-2012
- Exhibit 99: Razadyne Alzheimer's Disease Sales ($US), by Country, 2007-2012
- Exhibit 100: Summary of Forest Laboratories' Alzheimer's Disease Product
Portfolio
- Exhibit 101: Physician Perceptions of Forest in Alzheimer's Disease
- Exhibit 102: Summary of Lundbeck's Alzheimer's Disease Product Portfolio
- Exhibit 103: Physician Perceptions of Namenda
- Exhibit 104: Physician Use of Namenda in Moderate to Severe AD Patients
- Exhibit 105: Physician Use of Namenda in Mild to Moderate AD Patients
- Exhibit 106: Reasons Physicians Do Not Prescribe Namenda to Moderate to
Severe AD Patients
- Exhibit 107: Ongoing Clinical Trials for Namenda
- Exhibit 108: Namenda Alzheimer's Disease Sales ($US), By Region, 2007-2012
- Exhibit 109: Namenda Alzheimer's Disease Sales ($US), By Formulation,
2007-2012
- Exhibit 110: Namenda Alzheimer's Disease Sales ($US), by Country, 2007-2012
- Exhibit 111: Summary of Wyeth's Top Pharmaceutical Products, 2007
- Exhibit 112: Summary of Wyeth's Alzheimer's Disease Product Portfolio
- Exhibit 113: Summary of Elan's Top Biopharmaceutical Brands, 2007
- Exhibit 114: Summary of Elan's Alzheimer's Disease Product Portfolio
- Exhibit 115: Physicians' Expected Effect of Emerging Drug Classes on AD
Disease Progression
- Exhibit 116: Physicians' Familiarity with Late-Stage Development
Alzheimer's Disease Drugs
- Exhibit 117: Bapineuzumab Alzheimer's Disease Sales ($US), 2007-2012
- Exhibit 118: Expected Bapineuzumab Alzheimer's Disease Sales ($US), by
Country, 2007-2012
- Exhibit 119: Bapineuzumab, Expected Price per Day ($US), by Country
- Exhibit 120: Summary of Eli Lilly's Top Therapeutic Areas
- Exhibit 121: Summary of Eli Lilly's Alzheimer's Disease Product Portfolio
- Exhibit 122: LY-2062430 Alzheimer's Disease Sales ($US), 2007-2012
- Exhibit 123: Expected LY-2062430 Alzheimer's Disease Sales ($US), by
Country, 2007- 2012
- Exhibit 124: LY-2062430, Expected Price per Day ($US), by Country
- Exhibit 125: Summary of Medivation's Development Spend, 2003-2007
- Exhibit 126: Summary of Medivation's Product Development Portfolio
- Exhibit 127: Dimebon's Alzheimer's Disease Sales ($US), 2007-2012
- Exhibit 128: Expected Dimebon Alzheimer's Disease Sales ($US), by Country,
2007- 2012
- Exhibit 129: Dimebon, Expected Price per Day ($US), by Country
- Exhibit 130: Alzheimer's Disease Market ($US), Major Markets, 2007-2012
(Tabular Format)
- Exhibit 131: Alzheimer's Disease Market ($US), Major Markets, 2007-2012
(Graphical Format)
- Exhibit 132: Timeline of Key Events in the Alzheimer's Disease Market
- Exhibit 133: Key Launch Events, Alzheimer's Disease Market, 2007-2012
- Exhibit 134: Expected Generic Entries, Alzheimer's Disease Market,
2007-2012
- Exhibit 135: U.S. Market Dynamics, by Drug Class, 2007-2012
- Exhibit 136: European Market Dynamics for Alzheimer's Disease, by Drug
Class, 2007- 2012
- Exhibit 137: Japanese Market Dynamics in Alzheimer's Disease, by Drug
Class, 2007- 2012
- Exhibit 138: Alzheimer's Disease Market ($US), by Country, 2007-2012
- Exhibit 139: Alzheimer's Market ($US), by Class, 2007 and 2012
- Exhibit 140: Alzheimer's Market ($US), Competitors by Brand, 2007-2012
(Graphical Format)
- Exhibit 141: Alzheimer's Market ($US), Competitors by Brand, 2007-2012
(Tabular Format)
- Exhibit 142: Alzheimer's Market ($US), by Company, 2007-2012
- Exhibit 143: Prevalent and Diagnosed Alzheimer's Disease Cases, Major
Markets, 2007-2012
- Exhibit 144: Diagnosed Alzheimer's Disease Cases, by Country, Major
Markets, 2007- 2012
- Exhibit 145: Prevalent and Diagnosed Alzheimer's Disease Cases, by
Country, Major Markets, 2007-2012
- Exhibit 146: Adjusted Price of Aricept due to Generic Erosion, 2007-2012
- Exhibit 147: Adjusted Price of Razadyne due to Generic Erosion, 2007-2012
- Exhibit 148: Adjusted Price of Exelon due to Generic Erosion, 2007-2012
|
Related Report
|
View Cart
